Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous hematopoietic stem cell transplantation (AHSCT) is a cellular therapy being investigated by the Makati Medical Center for the treatment of multiple sclerosis (MS). The procedure involves the mobilization and collection of a patient's own hematopoietic stem cells, followed by a reduced-intensity immunoablative conditioning regimen known as BEAM (carmustine, etoposide, cytarabine, and melphalan). This chemotherapy regimen is designed to deplete the patient's existing, autoreactive immune system. Subsequently, the harvested stem cells are reinfused into the patient to facilitate the reconstitution of a new, functional immune system that lacks the pathogenic memory cells responsible for MS progression. This specific protocol is being evaluated in a Phase 1, patient-sponsored clinical trial (NCT03113162) targeting patients with progressive forms of the disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous hematopoietic stem cells (Makati Medical Center).